Experimental Roche breast cancer drug slows tumor growth, study shows

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared to 6.4 months in the group receiving the alternative treatment of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The difference is considered …
See all stories on this topic »